NCT05875532View on ClinicalTrials.gov

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

CompletedOBSERVATIONAL
Enrollment

34,960

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Lung Diseases, Interstitial
Trial Locations (1)

06877

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY